Eltrombopag-d3

CAT: 0804-HY-W713365Size: 1 EachDry Ice: NoHazardous: No
CAT#:0804-HY-W713365Size:1 Each
Selected
PRICE
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
Eltrombopag-d3 (SB-497115-d3) is deuterium labeled Eltrombopag. Eltrombopag (SB-497115) is an orally active thrombopoietin receptor nonpeptide agonist. Eltrombopag owns thrombopoietic activity, and has been used to research low blood platelet counts with chronic immune thrombocytopenia. Eltrombopag can be used for the research of cardiovascular. Eltrombopag also has highly inhibitory effects against multidrug resistant Staphylococcus aureus. Eltrombopag can induce apoptosis in hepatocellular carcinomab (HCC) as well[1][2][3][4][5].
CAS Number
[1133710-20-9]
Product Name Alternative
SB-497115-d3
UNSPSC
12352005
Target
Apoptosis; Bacterial; Isotope-Labeled Compounds; Thrombopoietin Receptor
Related Pathways
Anti-infection; Apoptosis; Immunology/Inflammation; Others
Applications
COVID-19-immunoregulation
Field of Research
Cancer; Infection; Cardiovascular Disease
Smiles
O=C(O)C1=CC(C2=C([2H])C([2H])=C([2H])C(N/N=C3C(C)=NN(C/3=O)C4=CC=C(C(C)=C4)C)=C2O)=CC=C1
Molecular Formula
C25H19D3N4O4
Molecular Weight
445.49
References & Citations
[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Erickson-Miller CL, et al. Preclinical activity of eltrombopag (SB-497115), an oral, nonpeptide thrombopoietin receptor agonist. Stem Cells. 2009 Feb;27 (2) :424-30.|[3]Erickson-Miller CL, et al. Discovery and characterization of a selective, nonpeptidyl thrombopoietin receptor agonist. Exp Hematol. 2005 Jan;33 (1) :85-93.|[4]Lee H, et al. Repurposing Eltrombopag for Multidrug Resistant Staphylococcus aureus Infections. Antibiotics (Basel) . 2021 Nov 9;10 (11) :1372.|[5]Juan Zhu, et al. Identification of Eltrombopag as a Repurposing Drug Against Staphylococcus epidermidis and its Biofilms. Curr Microbiol. 2021 Feb 21.|[6]Kurokawa T, et al. The Eltrombopag antitumor effect on hepatocellular carcinoma. Int J Oncol. 2015 Nov;47 (5) :1696-702.
Shipping Conditions
Room temperature
Scientific Category
Isotope-Labeled Compounds
Clinical Information
No Development Reported

Related Products

CatalogName
HY-15306-01Eltrombopag
HY-15306R-01Eltrombopag (Standard)
HY-15306SEltrombopag-13C4
HY-15306A-01Eltrombopag (Olamine)
HY-15306AR-01Eltrombopag (Olamine) (Standard)
HY-153239-01Eltrombopag methyl ester
HY-15398S3-01Vitamin D3-d3
HY-132348S1Granisetron-d3 (1-methyl-d3)
HY-150954SL-Methionine-d3 (S-methyl-d3) Methyl-d3-sulfonium Chloride
HY-B1213AS-01Trimipramine-d3 (N-methyl-d3) (maleate)

Alternative Products

CatalogName
TRC-E508003-25MGEltrombopag-d3
MBS3604661-01Eltrombopag

Popular Products